Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials.

Wu, Jiangfan; Zhao, Xiaofang; Chen, Huanhuan; Zhu, Shenyin

Wu, Jiangfan; Zhao, Xiaofang; Chen, Huanhuan; Zhu, Shenyin.

Afiliação

Wu J; Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; School of Pharmacy, Chongqing Medical University, Chongqing, China.
Zhao X; Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; School of Pharmacy, Chongqing Medical University, Chongqing, China.
Chen H; Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; School of Pharmacy, Chongqing Medical University, Chongqing, China.
Zhu S; Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: zhushenyin@cqmu.edu.cn.

J Diabetes Complications ; 36(12): 108352, 2022 12.

Article em En | MEDLINE | ID: mdl-36370667

Assuntos

Diabetes Mellitus Tipo 2; Síndrome Metabólica; Inibidores do Transportador 2 de Sódio-Glicose; Adulto; Humanos; Inibidores do Transportador 2 de Sódio-Glicose/uso terapêutico; Inibidores do Transportador 2 de Sódio-Glicose/farmacologia; Pressão Sanguínea; Síndrome Metabólica/tratamento farmacológico; Ensaios Clínicos Controlados Aleatórios como Assunto; Redução de Peso; Hipoglicemiantes/uso terapêutico

Palavras-chave

Antidiabetic drug; Meta-analysis; Metabolic benefit; SGLT 1/2 inhibitor; Sotagliflozin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Metabólica / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google